Terconazole (Terazol 7) is a synthetic triazole derivative structurally related to fluconazole, antifungal Terconazole seems to disrupt cell wall synthesis by inhibiting biosynthesis of ergosterol or other sterols, damaging the fungal cell membrane, altering its permeability, and promoting loss of essential intracellular elements. Terconazole is active against Candida sp.

Terconazole effectively inhibits the growth of Candida albicans ATCC 44859 in a concentration-dependent manner, demonstrating limited effects at 0.1 to 10 μM when cultured on media promoting the cell form. Its inhibitory impact on yeast cell viability varies across different Candida strains and species. Notably, C. albicans ATCC 44859's susceptibility to terconazole significantly increases on Eagle minimum essential medium, which encourages mycelium formation. The effects of terconazole range from inhibiting mycelia development at 0.1 μM to causing complete necrosis at 100 μM. Moreover, terconazole prevents the morphogenetic shift from the yeast to the filamentous form at concentrations between 0.008 and 0.05 microgram/mL.

A three-day, once-daily, intravaginal administration of 0.8% terconazole typically ensures a functional therapeutic duration of seven days, owing to sustained, elevated levels of the biologically active antifungal in the vagina. Terconazole is well-tolerated, with no side effects reported at any concentration[2].